Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology

Hayato Tada, Soichiro Usui, Kenji Sakata, Masayuki Takamura and Masa-aki Kawashiri

Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

1. Introduction

Based on a series of evidences, cholesterol has been established as a causal factor for atherosclerosis. Firstly, cholesterol is deposited in coronary atherosclerotic plaque1). Secondly, cholesterol-fed animals develop atherosclerotic plaque2). Thirdly, epidemiological studies have shown the positive relationship between cholesterol and atherosclerotic diseases3). Fourthly, familial hypercholesterolemia has been shown to accompany premature coronary artery disease4); on the other hand, familial hypobetalipoproteinemia has been shown as having less of a prevalence of such disease5). Finally, lowering (LDL) cholesterol via any means has been shown to reduce atherosclerotic cardiovascular diseases (ASCVD) regardless of the patients’ backgrounds6-9). When we think about LDL cholesterol value, the “normal” range is typically set to 70 to 139 mg/dl based on the distribution. We feel safe to see if the value is around 110 mg/dl because it is nearly the “mean” value. If the value is below 70 mg/dl, the value is reported as “abnormally low” to us even under the secondary prevention settings. This situation doesn’t make sense, since there are plenty of evidences suggesting that such an “abnormally low” LDL cholesterol level is associated with better clinical outcomes, especially among the patients with ASCVD, and the current clinical guidelines are accepting this fact10, 11). In the current era where we can use statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, LDL cholesterol level can be reduced far greater than in past decades, raising a critical question: How low the LDL cholesterol can be? Most of the cardiologists have a kind of hesitation to further reduce their LDL cholesterol level despite the clinical guidelines stating that...
LDL cholesterol should be lower than 70 mg/dl in a portion of high-risk patients\textsuperscript{12}. In this review article, we would like to provide lines of evidence clearly showing that “super-aggressive” LDL cholesterol lowering is not always considered as such. Rather, we need to rethink about the optimal range of LDL cholesterol level, instead of “normal” or “average” range.

2. Considerations from Extreme Cases

It is quite easy to understand the fact that LDL cholesterol is associated with ASCVD when we have a chance to see only a single case with homozygous FH. The untreated patients with homozygous FH whose LDL cholesterol levels are quite high are exhibiting premature ASCVD without exception. Interestingly, a simple treatment; namely, LDL cholesterol lowering, regardless of strategies, has been shown to literally save their lives\textsuperscript{13}. Additionally, we experience brothers with compound heterozygous FH where the older brother who had started treatment at the age of 23 exhibited repeated coronary events, whereas, the younger brother who had been treated since the age of 15 had been event-free for a long period, despite the similar LDL cholesterol levels based on the same mutations (NM_000527.4(LDLR):c.2054C>T (p.Pro685Leu)/NM_000527.4(LDLR):c.2431A>T (p.Lys811Ter)) (Fig. 1). The phenotypic difference between them clearly indicates that earlier intervention for LDL cholesterol can be quite beneficial even for such extreme cases. Moreover, several phenocopies of this situation with extremely high LDL cholesterol, including autosomal recessive hypercholesterolemia (ARH)\textsuperscript{14} and sitosterolemia\textsuperscript{15} caused by different genetic mutations, exhibit similar phenotypes, including tendon/cutaneous xanthomas, and premature ASCVD, similar to those observed in homozygous FH\textsuperscript{16}. Those cases simply indicate that LDL cholesterol is the causal factor of this situation regardless of genetic etiology. On the other hand, findings from the patients exhibiting extremely low LDL cholesterol with any genetic backgrounds could also tell us a lot about the relationship between LDL cholesterol and ASCVD. Our patient with abetalipoproteinemia (ABL) caused by microsomal triglyceride transfer protein (MTTP) mutations (LDL cholesterol=0 mg/dl) did not exhibit any coronary plaque nor aortic calcifications at the age of 51 (Fig. 2), although he suffers from spinocerebellar ataxia, and retinal pigmentary degeneration due to lack of fat-soluble vitamin\textsuperscript{17}. On the contrary, we have shown an interesting case of homozygous familial hypobetalipoproteinemia (FHBL) whose LDL cholesterol was as low as 1 mg/dl\textsuperscript{18}. The patient did not exhibit any complications relating to fat-soluble vitamin deficiency, as described above, probably due to his preserved HDL cholesterol (HDL cholesterol \textasciitilde 60 mg/dl) level containing fat-soluble vitamins. It would be important to see that none of the family members whose LDL cholesterol was quite low had atherosclerotic diseases. Moreover, we experience sisters working as nurse practitioners whose LDL cholesterol levels are \textasciitilde 40 mg/dl, caused by a loss-of-function of \textit{PCSK9} gene\textsuperscript{19}. All of the mutation carriers exhibiting low LDL cholesterol do not have any ASCVD, or any other clinical complications, including liver dysfunction. Those individuals carrying those mutations simply showed us that very low LDL cholesterol level over a long period is not so harmful, but rather, is beneficial for their preventive cardiology. Also, it would be quite interesting to understand that novel pharmacological interventions for LDL-lowering have been developed based on the findings obtained from those extreme cases\textsuperscript{5, 20-23} (Table 1).

3. Considerations from Human Genetics

As stated above, rare genetic variations, for example, mutation(s) involving loss of function in LDL receptor gene (namely, FH), are robustly associated with elevated LDL cholesterol level and ASCVD risk. On the other hand, loss of function mutation(s) in apolipoprotein B (\textit{APOB}) gene (namely, FHBL) are robustly associated with reduced LDL cholesterol level and ASCVD risk. The same situations are applicable to ATP-binding cassette sub-family G member 5 (\textit{ABCG5}) (both elevated)\textsuperscript{24}, angioptietin-like 3 (\textit{ANGPTL3}) (both reduced)\textsuperscript{22}, and \textit{PCSK9} (both reduced)\textsuperscript{23}. It is interesting to note that LDL cholesterol levels are positively associated with ASCVD regardless of genes and diseases. In addition to such rare genetic variations associated with Mendelian LDL disorders, common genetic variations associated with LDL cholesterol appear to be related with ASCVD. The magnitude of the effect on ASCVD is associated with LDL cholesterol level, and also such magnitude observed in genetic studies is far greater than that observed in clinical trials, suggesting that earlier intervention on LDL cholesterol may have a greater effect for preventive ASCVD. On the other hand, genetic variants associated with HDL cholesterol were not associated with ASCVD\textsuperscript{25}, consistent with negative results of RCT targeting lower HDL cholesterol\textsuperscript{26-28}.

4. Considerations from Clinical Trials Aiming to Reduce LDL Cholesterol Aggressively

Since the establishment of clinical usefulness of statins, there are debates regarding super-aggressive
LDL cholesterol lowering therapies, including targeting cholesterol levels much lower than 100 mg/dl, as well as the additional drugs on top of statins. Regarding the first matter, a RCT named EMPATHY study, targeting LDL cholesterol level <70 mg/dl using mainly statins among high-risk Japanese diabetic patients with primary prevention setting, revealed beneficial effect. In this study, patients receiving aggressive LDL cholesterol lowering therapies (mean LDL cholesterol level was 76.5 mg/dl) exhibited significantly lower ischemic stroke events than those with standard care (mean LDL cholesterol level was 104.1 mg/dl). Moreover, high-dose statin therapy reaching to LDL cholesterol level at 76.6 mg/dl has been shown to be better than low-dose statin therapy reaching to LDL cholesterol level at 91 mg/dl among Japanese secondary prevention patients. As for the second matter, recent mega RCT using ezetimibe, PCSK9 inhibitors, and a cholesteryl ester transfer protein (CETP) inhibitor on top of statins consistently revealed that additional beneficial effects could be obtained through such super-aggressive LDL chol-
Fig. 2. Images of coronary computed tomography and carotid ultrasound in a patient with ABL
A. Coronary computed tomography obtained in a patient with ABL. There are no stenotic lesions nor any calcifications identified in coronary arteries.
B. Carotid ultrasound image obtained in a patient with ABL. There are no stenotic lesions or intima-media thickness in right common carotid artery.
C. Carotid ultrasound image obtained in a patient with ABL. There are no stenotic lesions or intima-media thickness in left common carotid artery.
ABL, abetalipoproteinemia; RCA, right coronary artery; LAD, Left anterior descending coronary artery; LCX, Left circumflex coronary artery

Table 1. Novel pharmacological interventions for LDL-lowering

| Target  | Deficiency or carriers of PTV | Compounds | Randomized controlled trials | Mendelian randomization |
|---------|------------------------------|-----------|-----------------------------|------------------------|
| NPC1L1  | Heterozygous carriers (1 in 650 individuals) | Ezetimibe | IMPROVE-IT | Ref 20 |
| PCSK9   | Familial hypobetalipoproteinemia | Evolocumab | FOURIER | Ref 23 |
|         |                              | Alirocumab | ODESSEY OUTCOMES            |                        |
| MTTP    | Abetalipoproteinemia          | Lomitapide | NA                          | NA                     |
| APOB    | Familial hypobetalipoproteinemia | Mipomersen | NA                           | Ref 5                 |
| ANGPTL3 | Familial combined hypolipoproteinemia | Evinacumab | NA                           | Ref 22                |
| ACLY    | NA                           | Bempedoic Acid | NA                         | Ref 21                |

NPC1L1, Niemann-Pick C1-Like 1; PCSK9, proprotein convertase subtilisin-kexin type 9; MTTP, microsomal triglyceride transfer protein; APOB, apolipoprotein B; ANGPTL3, Angiopoietin-like 3; Ref, reference, NA, not available; ACLY, ATP citrate lyase.
terol lowering therapies in proportion to the absolute degree of LDL cholesterol lowering. It is of note that ASCVD events seemed to decline with achieved LDL cholesterol, to a level of approximately 30 mg/dl in ODYSSEY OUTCOMES (using alirocumab), and to a level of approximately 10 mg/dl in FOURIER (using evolocumab). Those observations collectively make us confident that the lower the LDL cholesterol, the better it could be achievable, at least at the range of LDL cholesterol ~30 mg/dl in patients with ASCVD. Moreover, Table 2 summarizing the results obtained through RCT and Mendelian randomization studies focusing on protein truncating variants (extreme situations) clearly indicates that super aggressive as well as earlier LDL-C lowering should be beneficial.

5. Lessons from Professors. Brown and Goldstein

In addition to the observations from those RCT, professors Brown and Goldstein, both of whom are Nobel laureates, suggested that the levels of cholesterol in our industrialized societies are inappropriately high. This comment was derived from three different important aspects of nature: 1) a level of LDL cholesterol in serum of 25 mg/dl would be sufficient to nourish body cells with cholesterol, estimated by the experimental studies showing that LDL receptor binds LDL optimally when the lipoprotein is present at a cholesterol concentration of 2.5 mg/dl. And it has been shown that there is a 10-to-1 gradient between concentrations of LDL in plasma and interstitial fluid; 2) plasma LDL cholesterol levels of other mammals without development of atherosclerosis are generally less than 80 mg/dl; 3) LDL cholesterol level in newborn humans is approximately 30 mg/dl; 4) when humans are raised on a low fat diet, the plasma LDL cholesterol levels tend to stay in the range of 50 to 80 mg/dl.

6. Lessons from Monkeys, our Estimable Ancestors

Let me remind you that LDL cholesterol levels of monkeys, who are our estimable ancestors, have been shown to be as low as ~30 mg/dl. Japanese macaque, whose life span is around 20 to 30 years, hardly exhibit ASCVD. Typically, wild monkeys have to survive in a natural field, requiring LDL cholesterol because of the incident of bleedings and/or infections. Accordingly, it could be skeptical that humans, especially, those living in industrialized societies, need a LDL cholesterol level as high as ~100 mg/dl. In this regard, “standard” levels are usually determined based on “average” values, not bade on “healthy” values in any biomarkers, including LDL cholesterol. Thus, it would be better to rethink “standard” levels of cholesterol.

7. Potential Concerns for Low LDL Cholesterol

In spite of a series of beneficial evidences as stated above, there are still many cardiologists who have some concerns about low LDL cholesterol, such as Alzheimer’s disease, dementia, Parkinson’s disease, and hemorrhagic stroke. In this regard, recent Mendelian randomization studies have suggested that low LDL cholesterol levels due to PCSK9 and hydroxymethylglutaryl-CoA reductase (HMGCR) variants had no causal effect on high risk of Alzheimer’s disease, vascular dementia, any dementia, or Parkinson’s disease; instead, low LDL cholesterol levels may have a causal effect in reducing the risk of Alzheimer’s disease. On the other hand, another study showed strong positive associations of LDL cholesterol with ischemic stroke and inverse associations with hemorrhagic stroke; however, lowering LDL cholesterol appears to have net benefit for prevention of overall vascular events.

Table 2. Effects of randomized controlled trials and Mendelian randomization study in PTV on LDL-C and on ASCVD

| Gene   | RCT Trial name | LDL cholesterol reduction (mg/dl) | ASCVD reduction (%) | Mendelian randomization study in PTV | LDL cholesterol reduction (mg/dl) | ASCVD reduction (%) |
|--------|----------------|----------------------------------|---------------------|-------------------------------------|----------------------------------|---------------------|
| APOB   | NA             | NA                               | NA                  | NA                                  | 43                               | 72                  |
| CETP   | REVEAL         | 26                               | 9                   | 12                                  | 30                               | 53                  |
| NPC1L1 | IMPROVE-IT     | 17                               | 6                   | 12                                  | 53                               | 88                  |
| PCSK9  | FOURIER/ODYSSEY| 62/48                            | 15/15               | 21                                  | 88                               |                     |

RCT, randomized controlled trial; PTV, protein truncating variant; ASCVD, atherosclerotic cardiovascular disease; APOB, apolipoprotein B; CETP, cholesteryl ester transfer protein; NPC1L1, Niemann-Pick C1-Like 1; PCSK9, proprotein convertase subtilisin-kexin type 9; NA, not available.
burden” in these particular patients. Namely, the integrated, accumulated sum of LDL cholesterol burden appears to lead them for their premature ASCVD. In other words, target LDL cholesterol level should be quite low if the patients with FH started treatment too late, whereas, that can be moderate under the situation where LDL cholesterol lowering is started early enough. To support this notion, a recent study showed that the patients with FH who had been treated moderately (LDL cholesterol level from 237 mg/dl to 160 mg/dl) since the mean age of 13 years exhibited far better prognoses compared with their age-matched relatives with FH46). Accordingly, “the earlier, the better” concept seems to be applicable to this extreme case, and we believe that it should also be true for non-FH hyper LDL cholesterolemia47).

Moreover, we know that there are large variations of severity of disease (susceptibility to ASCVD) even among the patients with FH47-51). At least a part of it has been explained by their genetic status of FH and their physical signs of FH52). Another study has shown that accumulated effects of common genetic variations, in addition to rare mutation(s), which lead them to FH are contributing to their phenotypic variability53). Accordingly, the ideal strategy of LDL cho-

8. Precision Medicine of LDL Cholesterol Lowering

As stated, LDL cholesterol, as an important causal factor for ASCVD should be reduced as much as possible, especially in the secondary prevention settings. However, there is an emerging concept of precision medicine in almost all fields of medicine, including preventive cardiology. In the statin era, it has been shown that the effectiveness of this drug seems to be equal among a set of clinical subgroups, such as hypertension, diabetes, smoking, and so on6). On the other hand, there are a series of patients who exhibit greater responsiveness to ezetimibe, including, patients with diabetes, and those with ABCG5 or ABCG8 genetic mutation(s)39-41). Moreover, sub-analyses from recent clinical trials using PCSK9 inhibitors have suggested that there are several types of groups of patients who had greater benefit via this costly drug, including those with peripheral artery disease, elevated Lp(a) levels, or with high polygenic risk42-45).

On the other hand, when we try to reduce LDL cholesterol among the patients with FH, we typically use the multiple LDL-lowering therapies listed above. However, there is an emerging concept of “cholesterol burden” in these particular patients. Namely, the integrated, accumulated sum of LDL cholesterol burden appears to lead them for their premature ASCVD. In other words, target LDL cholesterol level should be quite low if the patients with FH started treatment too late, whereas, that can be moderate under the situation where LDL cholesterol lowering is started early enough. To support this notion, a recent study showed that the patients with FH who had been treated moderately (LDL cholesterol level from 237 mg/dl to 160 mg/dl) since the mean age of 13 years exhibited far better prognoses compared with their age-matched relatives with FH46). Accordingly, “the earlier, the better” concept seems to be applicable to this extreme case, and we believe that it should also be true for non-FH hyper LDL cholesterolemia47).

Moreover, we know that there are large variations of severity of disease (susceptibility to ASCVD) even among the patients with FH47-51). At least a part of it has been explained by their genetic status of FH and their physical signs of FH52). Another study has shown that accumulated effects of common genetic variations, in addition to rare mutation(s), which lead them to FH are contributing to their phenotypic variability53). Accordingly, the ideal strategy of LDL cho-

Fig. 3. Precision medicine for FH

When we encounter an individual whose LDL cholesterol level is ≥ 180 mg/dl, then we have to consider a clinical as well as genetic diagnosis of FH. Additionally, additional risk stratification can be considered based on their common genetic variations, and their imaging. According to this information, we can select the best approach for their LDL cholesterol reduction. FH: familial hypercholesterolemia; SNV: single nucleotide variation
cholesterol lowering should be quite individual-specific, including genetic backgrounds, and the timing of treatments (Fig. 3).

9. Conclusion

In this paper, we have repeatedly emphasized that LDL cholesterol is a causal risk factor for ASCVD. Also we have learned from lines of evidence that super-aggressive LDL cholesterol lowering therapies, at least at around 30 mg/dl, are safe. We need to rethink what is the optimal range of LDL cholesterol level, instead of “normal”, or “average” range, based on a series of evidences from clinical trials, human genetics, and biology.

Conflict of Interest Disclosures

None.

Acknowledgements and Notice of Grant Support

None.

References

1) Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med, 1991; 91: 35-95
2) Friedman M. Pathogenesis of the spontaneous atherosclerotic plaque. A study on the cholesterol-fed rabbit. Arch Pathol, 1963; 76: 318-329
3) Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med, 1971; 74: 1-12
4) Mabuchi H. Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan. J Atheroscler Thromb, 2017; 24: 189-207
5) Peloso GM, Nomura A, Khera AV, Chaffin M, Won HH, Ardissino D, Danesh J, Schunkert H, Wilson JG, Samani N, Erdmann J, McPherson R, Watkins H, Saleheen D, McCarthy S, Teslovich TM, Leader JB, Lester Kirchner M, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tolstrup J, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188
6) Tada H, Kawashiri MA, Nohara A, Inazu A, Kobayashi J, Yasuda K, Mabuchi H, Yamagishi M, Hayashi K. Lipid management in a Japanese community: Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984
7) Makino H, Koezuka R, Tamanaha T, Yasuda K, Mabuchi H, Yamagishi M, Hayashi K. Lipid management in a Japanese community: Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. J Atheroscler Thromb, 2017; 24: 338-345
8) Makino H, Koezuka R, Tamanaha T, Ogura M, Matsuki K, Hosoda K, Harada-Shiba M. Familial Hypercholesterolemia and Lipoprotein Apheresis. J Atheroscler Thromb, 2019; 26: 679-687
9) Tada H, Kawashiri MA, Ikewaki K, et al. Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet, 2012; 5: 35-41
10) Tada H, Nohara A, Inazu A, et al. Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. J Atheroscler Thromb, 2018; 25: 783-789
11) Tada H, Kawashiri MA, Yamagishi M. Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary
Artery Disease. J Atheroscler Thromb, 2017; 24: 452-461
17) Yang XP, Inazu A, Yagi K, Kajinami K, Koizumi J, Mabuchi H. Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene. Arterioscler Thromb Vasc Biol, 1999; 19: 1950-1955
18) Kawashiri MA, Tada H, Hashimoto M, Taniyama M, Nakano T, Nakajima K, Inoue T, Mori M, Nakanishi C, Konno T, Hayashi K, Nohara A, Inazu A, Koizumi J, Ishihara H, Kobayashi J, Hirano T, Mabuchi H, Yamagishi M. Extreme Contrast of Postprandial Remnant-Like Particles Formed in Abetalipoproteinemia and Homozygous Familial Hypobetalipoproteinemia. JIMD Rep, 2015; 22: 85-94
19) Tada H, Okada H, Nomura A, Nohara A, Takamura M, Kawashiri MA. A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene. Intern Med, 2020 in press
20) Myocardial Infarction Genetics Consortium Investigators, Stitziel NO, Won HH, Morrison AC, Golembiewski RM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, Goel A, Farrall M, Saleheen D, Ferrari P, König I, Assetta R, Merlini PA, Marzialino N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, Wilensky R, Rader DJ, Hovingh GK, Meitinger T, Kessler T, Kastrati A, Laugwitz KL, Siscovick D, Rotter JI, Hazen SL, Tracy R, Cresci S, Spertus J, Jackson R, Schwartz SM, Palmer C, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Collins
31) HPS3/TIMI55–REVEAL Collaborative Group, Bowman Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cum- AIM-HIGH Investigators, Boden WE, Probstfield JL, Hulley S, Grady D, Bush T, Furberg C, Herrington D, E, Landray MJ. Effects of Anacetrapib in Patients with Japanese Patients With Stable Coronary Artery Disease Nagai R. High-Dose Versus Low-Dose Pitavastatin in Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishikawa M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPA- TREY Investigators. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care, 2018; 41: 1275-1284

37) Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjerg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCGR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. BMJ, 2017; 357: j1648

38) Sun L, Clarke R, Bennett D, Guo Y, Walters RG, Hill M, Parish S, Millwood IY, Bian Z, Chen Y, Yu C, Lv J, Collins R, Chen J, Petö R, Li L, Chen Z; China Kadoorie Biobank Collaborative Group; International Steering Committee; International Co-ordinating Centre, Oxford; National Co-ordinating Centre, Beijing; Regional Co-ordinating Centres. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nat Med, 2019; 25: 569-574

39) Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Spinar J, Park JG, White JA, Bohula EA, Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy and Safety in Patients With Versus PROPER. Atherosclerosis, 2018; 274: 139-145

40) Yamaguchi J, Kawada-Watanabe E, Koyanagi R, Arashi H, Sekiguchi H, Nakao K, Toobaru T, Tanaka H, Oka T, Endo Y, Saito K, Uchida T, Matsui T, Ogawa H, Hagiwara N. Baseline serum sitosterol level as predictor of cardiovascular Outcomes and Safety in Patients With Versus Diabetes Mellitus: Results From IMPROVE-IT (Improved Outcomes of Outcomes: Vytorin Efficacy International Trial). Circulation, 2018; 137: 1571-1582

41) Tada H, Okada H, Nomura A, Takamura M, Kawashiri MA. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis, 2020; 19: 3

42) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis KW, Moriyusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019; 140: 103-112

33) Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, 2017; 390: 1962-1971

34) Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986; 232: 34-47

35) Takenaka A, Matsumoto Y, Nagaya A, Watanabe K, Goto S, Suryobroto B, Takenaka O. Plasma cholesterol levels in free-ranging macaques compared with captive macaques and humans. Primates, 2000; 41: 299-309

36) Fedigan, L., 1991. Lifespan and reproduction in Japanese macaque females. In: The Monkeys of Arashiyama: 35 Years of Research in Japan and the West, L. M. Fedigan & P. J. Asquith (eds.), State Univ. of New York Press, Albany, New York, pp. 140-154

37) Tada H, Okada H, Nomura A, Takamura M, Kawashiri MA. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis, 2020; 19: 3

40) Yamaguchi J, Kawada-Watanabe E, Koyanagi R, Arashi H, Sekiguchi H, Nakao K, Tobaru T, Tanaka H, Oka T, Endo Y, Saito K, Uchida T, Matsui T, Ogawa H, Hagiwara N. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidemia: A sub-analysis of HIJ-PROPER. Atherosclerosis, 2018; 274: 139-145

41) Tada H, Okada H, Nomura A, Takamura M, Kawashiri MA. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis, 2020; 19: 3

42) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis KW, Moriyusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019; 140: 103-112

33) Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, 2017; 390: 1962-1971

34) Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986; 232: 34-47

35) Takenaka A, Matsumoto Y, Nagaya A, Watanabe K, Goto S, Suryobroto B, Takenaka O. Plasma cholesterol levels in free-ranging macaques compared with captive macaques and humans. Primates, 2000; 41: 299-309

36) Fedigan, L., 1991. Lifespan and reproduction in Japanese macaque females. In: The Monkeys of Arashiyama: 35 Years of Research in Japan and the West, L. M. Fedigan & P. J. Asquith (eds.), State Univ. of New York Press, Albany, New York, pp. 140-154

37) Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjerg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCGR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. BMJ, 2017; 357: j1648

38) Sun L, Clarke R, Bennett D, Guo Y, Walters RG, Hill M, Parish S, Millwood IY, Bian Z, Chen Y, Yu C, Lv J, Collins R, Chen J, Petø R, Li L, Chen Z; China Kadoorie Biobank Collaborative Group; International Steering Committee; International Co-ordinating Centre, Oxford; National Co-ordinating Centre, Beijing; Regional Co-ordinating Centres. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nat Med, 2019; 25: 560-574

39) Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Spinar J, Park JG, White JA, Bohula EA, Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy and Safety in Patients With Versus Diabetes Mellitus: Results From IMPROVE-IT (Improved Outcomes of Outcomes: Vytorin Efficacy International Trial). Circulation, 2018; 137: 1571-1582

40) Yamaguchi J, Kawada-Watanabe E, Koyanagi R, Arashi H, Sekiguchi H, Nakao K, Tobaru T, Tanaka H, Oka T, Endo Y, Saito K, Uchida T, Matsui T, Ogawa H, Hagiwara N. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidemia: A sub-analysis of HIJ-PROPER. Atherosclerosis, 2018; 274: 139-145

41) Tada H, Okada H, Nomura A, Takamura M, Kawashiri MA. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis, 2020; 19: 3

42) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis
and Population Health - Time to Move to a Cumulative Exposure Model. Circulation, 2020 in press

48) Tada H, Kawashiri MA, Nomura A, Teramoto R, Hosomichi K, Nohara A, Inazu A, Mabuchi H, Tajima A, Yamagishi M. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol, 2018; 12: 1436-1444

49) Tada H, Kawashiri MA, Okada H, Teramoto R, Konno T, Yoshimuta T, Sakata K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M, Hayashi K. Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. J Am Cardiol, 2015; 115: 724-729

50) Tada H, Kawashiri MA, Okada H, Nakahashi T, Sakata K, Nohara A, Inazu A, Mabuchi H, Yamagishi M, Hayashi K. Assessment of arterial stiffness in patients with familial hypercholesterolemia. J Clin Lipidol, 2018; 12: 397-402

51) Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J, 2017; 38: 1573-1579

52) Fahed AC, Wang M, Chaffin M, Bick AG, Patterson C, Natarajan P, Lebo M, Batra P, Ng K, Ellinor PT, Philippakis AA, Kathiresan S, Khera AV. Risk of Myocardial Infarction in Carriers of Familial Hypercholesterolemia Mutations is Modified by Common Variant Genetic Background or Adherence to a Healthy Lifestyle. Circulation, 2019; 140: A15044